Strattera 25mg Cap
USD150.00 – USD2,500.00
Strattera 25mg Cap
ATOMOXETINE (AT oh mox e teen) is used to treat attention deficit/hyperactivity disorder, also known as ADHD. It is not a stimulant like other drugs for ADHD. This drug can improve attention span, concentration, and emotional control. It can also reduce restless or overactive behavior.
Strattera 25mg Cap
Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
Additional information for the safe use of this product:
A comprehensive treatment programmed typically includes psychological, educational and social measures and is aimed at stabilizing patients with a behavioral syndrome characterized by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.
Pharmacological treatment is not indicated in all patients with this syndrome and the decision to use the drug must be based on a very thorough assessment of the severity of the patient’s symptoms and impairment in relation to the patient’s age and the persistence of symptoms.
Similar Generic Drugs : Atomoxetine: Oral capsule (10mg) | Atomoxetine: Oral capsule (100mg) | Atomoxetine: Oral capsule (60mg) | Atomoxetine: Oral capsule (80mg) | Atomoxetine: Oral capsule (40mg) | Atomoxetine: Oral capsule (18mg) | Atomoxetine: Oral capsule (25mg)
1. List of excipients
Starch, pregelatinised (Maize)
Capsule Shell Cap colourants:
10 mg: Titanium dioxide E 171
18 mg: Yellow iron oxide E172
25 mg, 40 mg, and 60 mg: FD&C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171
80 mg and 100 mg: Yellow iron oxide E172, Red iron oxide E172, Titanium dioxide E171
Capsule Shell Body colourants:
60 mg: Yellow iron oxide E172
10 mg, 18 mg, 25 mg and 80 mg: Titanium dioxide E 171
40 mg: FD&C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171
100 mg: Yellow iron oxide E172, Red iron oxide E172, Titanium dioxide E171
Edible Black Ink SW-9008 (containing Shellac and Black Iron Oxide E172) or Edible Black Ink SW-9010(containing Shellac and Black Iron Oxide E172).
3. Shelf life
4. Special precautions for storage
This medicinal product does not require any special storage conditions.
5. Nature and contents of container
Polyvinyl chloride (PVC)/polyethylene (PE)/ Polychlorotrifluoroethylene, PCTFE blister sealed with aluminium foil lid.
Available in pack sizes of 7, 14, 28 and 56 capsules. Not all pack sizes may be marketed.
6. Special precautions for disposal and other handling
The capsules are not intended to be opened. Atomoxetine is an ocular irritant. In the event of capsules content coming in contact with the eye, the affected eye should be flushed immediately with water, and medical advice obtained. Hands and any potentially contaminated surfaces should be washed as soon as possible.
Marketing authorisation holder
Eli Lilly Nederland B.V.
3528 BJ Utrecht
Marketing authorisation number(s)
STRATTERA 10 mg hard capsules:
STRATTERA 18 mg hard capsules:
STRATTERA 25 mg hard capsules:
STRATTERA 40 mg hard capsules:
STRATTERA 60 mg hard capsules:
STRATTERA 80 mg hard capsules:
STRATTERA 100 mg hard capsules:
Date of first authorisation/renewal of the authorisation
Date of first authorisation: 27 May 2004
Date of latest renewal: 27 May 2014
Date of revision of the text
26 January 2021
Detailed information on this medicinal product is available on the website of: UK/MHRA
|Pack of Strattera Capsule's||
30, 60, 120, 180, 500, 1000